Zentalis Pharmaceuticals stock heads toward October cancer data

Published on 10/05/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zentalis Pharmaceuticals stock faces two October clinical milestones after Leerink Partners set a USD 8.00 target on October 5, 2026. Q2 EPS came in at negative USD 0.59 versus negative USD 0.49 consensus.

ZNTL, US98943L1070, Illustration mit AI erstellt.

Zentalis Pharmaceuticals (ISIN US98943L1070) was last at USD 2.52 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 3.26 percent from the prior close. The next major company milestones are a DENALI Part 1b overall-survival presentation on October 23 and an ASPENOVA Phase 3 poster on October 26, as Investing.com reported on October 5, 2026.

October brings two clinical tests

The October 23 presentation in Madrid will cover overall-survival data from the DENALI Part 1b study, while the October 26 event will address the ASPENOVA trial in progress. Both events center on azenosertib, Zentalis Pharmaceuticals' investigational WEE1 inhibitor for ovarian cancer and other tumor types.

Zentalis Pharmaceuticals describes azenosertib as an oral, biomarker-driven treatment approach that is being studied in monotherapy and combination programs. The clinical readouts are therefore important because they address both efficacy data and the development path for the lead program.

Leerink target doubles to USD 8

Leerink Partners began coverage with an Outperform rating and a USD 8.00 price target, replacing its previous Market Perform view and USD 4.00 target, according to Investing.com on October 5, 2026. The target change is a concrete test of how much value analysts assign to the azenosertib data path.

The broader analyst view is less uniform. MarketBeat reported on October 5, 2026 that 10 analysts had a Hold consensus and an average 12-month price target of USD 6.75. At USD 2.52, the stock lies 62.7 percent below that average target.

Quarterly loss remains a risk

Zentalis reported diluted EPS of negative USD 0.59 for Q2 2026, missing the negative USD 0.49 consensus estimate by USD 0.10, according to MarketBeat. That miss keeps clinical execution and financing capacity central to the investment case while the company advances late-stage studies.

Stock stays below its yearly high

Zentalis Pharmaceuticals was last at USD 2.52 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 1.21 to USD 6.95, and its market capitalization was USD 179.4 million on that quote.